Intra-Cellular Therapies Announces Positive Topline Results from Study 402

everhopeful · September 9, 2020, 12:28pm

robertc · September 9, 2020, 1:57pm

This is good news. They used 2 different dosages. I am hoping they produce a 2nd dose of 28 mg besides the current 42 mg.
Saw one online bipolar patient review of Caplyta that was very positive.

Wave · September 9, 2020, 2:08pm

Yes,encouraging news

navr · November 29, 2020, 1:47am

Positive response from a patient on Caplyta:
youtube dot com/watch?v=jA1XSYBjhLo

Topic		Replies	Views
Intra-Cellular Therapies Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia News	4	771	September 12, 2017
Intracellular Theraputics reports mixed results with Lumateperone in Bipolar News	0	272	July 8, 2019
More on Lumateperone results in bipolar I and II News	9	500	November 29, 2020
Intra-cellular Therapies presentation January 15 News	16	531	January 22, 2020
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia Medications	0	38	November 5, 2024

Intra-Cellular Therapies Announces Positive Topline Results from Study 402

Related topics